Microsoft develops deep learning tool to combat SIDS

Data scientists form Microsoft have donated a newly developed tool to Seattle Children’s Research Institute to advance research into sudden infant death syndrome (SIDS). The team will also make the tool available to researchers around the globe.

Although SIDS deaths have plateaued at roughly 4,000 per year in the U.S. since the mid-1990s, researchers are working to discover its causes. A research team led by John Kahan, general manager for customer data and analytics at Microsoft, used deep learning technology and big data to develop methods to identify SIDS causes and craft preventative measures.

The team analyzed public data from the U.S. Centers for Disease Control and Prevention (CDC), including 27,000 sudden and unexplained infant deaths from 2004 to 2010. They then created machine learning and statistical models to interpret the data. These models allowed researchers to search factors such as parents’ age, level of prenatal care and birth order to evaluate how these factors affect SIDS.

The technology verified SIDS correlations already proved by researchers. New correlations were also identified, providing researchers with scientific processes to further SIDS studies.

"The potential of this tool to aid medical research and open new areas of exploration in identifying SIDS risk factors is both impactful and tremendously encouraging," said Nino Ramirez, director of the Center for Integrative Brain Research at Seattle Children's Research Institute. "I am even more amazed by the potential research implications this tool could have for other sudden death disorders like obstructive sleep apnea, epilepsy and mitochondrial diseases. Exploring the data visually ... could provide novel insights and inspire research into any one of these disorders."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.